Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Iqe Plc | IQE | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 10.54 | 09:20:17 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 10.54 |
| Industry Sector |
|---|
| TECHNOLOGY HARDWARE & EQUIPMENT |
| Top Posts |
|---|
Posted at 20/11/2024 09:23 by longtallsally Provonar, thinking about what you said, I suspect Americo went too early with the latest order of three or four Aixtron machines last year. I’m sure one will be put to good use in Taiwan but the others are likely lying dormant now we know IQE business has faltered.I suspect that the reality is IQE won’t start to potentially prosper again until 2026/2027, seeing as 2025 less than spectacular earnings forecasts have been reduced once more. As you point out, their focus now is to get to that point still functioning as a going concern. As investors in IQE we will just have to stick with it, as it’s obviously not going to be a quick turnaround. |
Posted at 19/11/2024 09:28 by longtallsally Looking forward I think as always with IQE the issue will be the timing of when to bank the inevitable next share price rise. A look at the chart and history tells us it is littered with huge rise and falls over the past 20 years after times of hope and the next disappointment. Unless IQE look like they will have to be fire sold next year the share price will recover, to some degree it always does, but perhaps with just lower highs (80p won’t be seen for many years again imo)If the Taiwan IPO is successfully handled and IQE don’t issue another profit warning on next years now reduced earnings then expect the share price to be in the 20s or 30s before this time next year. The problem for investors will be as happened this year people will get carried away yet again (see Crosswires end of year share price predictions list), BUT unless there is concrete proof of big new orders we would all be best ignoring anyone predicting huge revenue increases without such proof as it often comes to nothing (see Americo Lemos or Captain Calamity as he is now known). Personally if the share price does recover well into the 30s then I will be selling and not looking back. Holding IQE has been far too stressful and disappointing and if break even could be achieved then I would be satisfied to have just lost time but not money with my investment here. |
Posted at 18/11/2024 09:52 by fuji99 This is their R & D summary:"IQE is committed to technological leadership through research and development. We are able to offer innovative new products and technologies that meet the needs of our customers. Throughout our history, R&D at IQE has been strengthened by the company’s organic growth, global acquisitions and strategic partnerships. Today we are recognised as technology leaders and IQE continues to attract the brightest and best talent in our industry." If R & D does not deliver an output that meets the need of customers, (nobody buys it as proven by their decaying numbers), they are just wasting their time before they close shop. |
Posted at 18/11/2024 07:18 by a13878713 Cardiff, UK18 November 2024This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). Trading Update, Strategic Review and Proposed Financing IQE plc (AIM: IQE, "IQE" or the "Group"), the leading global supplier of compound semiconductor wafer products and advanced material solutions, provides a trading update for the year ending 31 December 2024.Revenue for the Full Year 2024 is expected to be broadly flat year-on-year, resulting in around £115m. In line with the rest of the industry, we are continuing to see a slower than anticipated recovery in key sectors driven by weak consumer demand in end markets. The group expects this to result in an Adjusted EBITDA of at least £5m.Strategic ReviewThe Board remains confident in IQE's long-term prospects because of the Group's leading position in providing advanced compound semiconductors across several market verticals and to a base of global marque customers. The Board believes there is significant value in IQE that is not currently reflected in its market capitalisation. Consequently, IQE announces today that it will be conducting a comprehensive strategic review of its asset base to ensure that it has a strong capital position to further invest in its core operations (the "Strategic Review"). The Board believes there is a significant market opportunity in IQE's core operations and remains focused on reducing its cost structure for profitable growth, servicing its customers and maximising value for shareholders.In the first instance, IQE will broaden its options in relation to the proposed IPO of its Taiwan operations to include all strategic options, including a full sale. The Board has retained Lazard to advise on the Strategic Review. The Strategic Review will be overseen by IQE's Board of Directors, with input from key stakeholders.Propose |
Posted at 13/11/2024 10:36 by crosswires Yes, all is not as it seems, some odd reporting …See below for transparency, today’s 50k buy and last weeks 101664 (to make a round number in my account, i’m a bit OCD on numbers!) I shan’t reveal my total holding, but it’s over 1m and my average is now down into the 20s. Trade date & time 13/11/24 at 08:42:19 Name IQE symbol IQE Action Buy Quantity 50,000 shares Price traded £0.10285 Settlement Date 15/11/2024 Settlement Period T+2 (2 days) Settlement Currency GBP Market Currency GBP Consideration £5,142.50 Commission £3.99 Total £5,146.49 Trade date & time 05/11/24 at 08:38:10 Name IQE symbol IQE Action Buy Quantity 101,664 shares Price traded £0.116147 Settlement Date 07/11/2024 Settlement Period T+2 (2 days) Settlement Currency GBP Market Currency GBP Consideration £11,807.97 Commission £3.99 Total £11,808.97 |
Posted at 05/11/2024 17:45 by boboty IQE to add 109 jobs and invest $305m expanding US operation in GreensboroEpiwafer and substrate maker IQE plc of Cardiff, Wales, UK has announced an expansion of its manufacturing facility in Greensboro, Guilford County, North Carolina, subject to customer commitments and funding from the US federal CHIPS and Science Act. The firm plans to add 109 jobs and invest $305m over several years.IQE has operated for more than a decade in Greensboro, where it has 72 staff, using molecular beam epitaxy (MBE) to manufacture epiwafers for the defense and aerospace industries. This potential investment would add complementary metal-organic chemical vapor deposition (MOCVD) epitaxy and provide a new technology for the production of chips serving the electric vehicle (EV) market."Greensboro has proven to be a strategic location for IQE and has provided access to exceptional talent," says interim CEO Jutta Meier. "We look forward to continuing our partnership with the city as we progress further with our application for Government funding via the CHIPS Act which, along with funding commitments from the State, will provide us with the capital to invest and expand our local footprint," she adds. |
Posted at 05/11/2024 12:35 by provonar Taking a look at the CHIPS act funding process a bit further:It's clear that acquiring state/local funding is a requirement before any CHIPS act (federal) funding is confirmed. Therefore, this $2M grant from Greensboro is one of the initial steps that IQE have to go through in order to secure CHIPS act funding (and is also why the local county/state is happy to put up the money - it gets more than matched by the federal level grant). That'll also be why there's the 'no commitment' statement from IQE in that I expect both grants rely on each other - IQE won't commit anything until the entire financial construction is confirmed. What's also clear is that there needs to be significant private investment coming in to kick-start the project the CHIPS act funding is for, which is reimbursed later. So that's probably where the Taiwan IPO comes into play - raising funds to start the NC expansion that then secures CHIPS funding. There could possibly be a further funding round depending on what is needed to secure the CHIPS funding. The CHIPS grant pay-outs will be awarded when milestones are met - I doubt we'll know what those milestones are in advance (employing a certain number of new personnel; installing so many tools etc.). The federal govt. may enter a profit-sharing deal for grants over $150M, which could affect this $305M target deal that IQE appear to be going for. Of course, you have to make profits to share any, which would be nice... There'll be further things that IQE can do - $305M buys a lot of epitaxy tools. All the ones purchased under CHIPS funding will certainly have to be placed in the US (Greensboro) - however, older tools at the NC site could be moved to other sites (i.e. Wales) in order to spread capacity. With the relatively recent purchase of three tools from Aixtron for GaN epitaxy, the fact that these went to both sites in the US and UK mean that GaN capacity expansion could spread across both sites (with the most up-to-date and majority of the capacity being in the US). All quite positive (for once), but definitely shouldn't count any chickens yet - which may be why the share price hasn't responded significantly so far (I'm sure this is all pretty old news to the funds - it may even explain why there was the rise earlier in the year off not a lot of news, the recent drop being possibly due to delayed plans - exacerbated now by the CEO leaving). Now, it could become even more interesting if IQE have plans to secure the equivalent Taiwanese version of the CHIPS act funding... DYOR |
Posted at 03/11/2024 15:22 by provonar Smorales,Thanks, that's a very interesting find. There is only one semiconductor firm on Gallimore Dairy Road, as far as I can see, and the descriptive wording obviously sounds like IQE. The "$305,000,000 million" looks like a typo, so I expect it's $305M. The 'personal property investment' looks like the distinction between fixed and moveable property - so this would be for investment in tools and other movable hardware to support the productino process, absolutely in-line with an expansion of epiwafer production to support GaN expansion for power applications. I was initially thinking the use of the term 'personal' meant the investment was private, but this doesn't look like the case - it's just a descriptor of the property that would be developed. So, indeed, given the amount (that IQE does not have), it looks like this is CHIPS act funding. I've checked the grants awarded so far ( and this one doesn't appear there - but this doesn't mean it's not in the pipeline. The only announced award in NC is for Wolfspeed for SiC wafer production expansion in Siler City, which is just down the road from Greensboro. Considering there has been $33B of grants and $28B in loans from the CHIPS act so far, this kind of amount is well within the realms of possibility. I'm not sure why IQE are being so cagey about being identified - possibly to avoid any undue local attention for getting a county hand-out, possibly to avoid notifying the competition, possibly because it's just the way a lot of businesses make this kind of local application for development incentives. Additionally, the size of this award would mean that IQE is duty-bound to make a market announcement - but they are possibly waiting for it to be confirmed (which is why the 'does not commit' statement is in there - getting the local incentive is one thing, sealing the deal on the national CHIPS grant is something else). It makes the departure of Mr. Lemos even more strange, if they had visibility of this coming down the tracks. Wild speculation of the options are: 1. He was poached by one of the bigger fish, possibly even back to Global Foundries to help with their planned expansion; 2. There's been yet another Boardroom rift and the funds have lost patience with the pace of the realignment of IQE; 3. Some impropriety that gave the Board no choice - Mr. Lemos doesn't come across as that kind of guy, but you never know; 4. Some personal matter of such life-changing significance that Mr. Lemos decided to step back. Hopefully things will be cleared up asap and this possible CHIPS award can be confirmed. |
Posted at 29/10/2024 14:34 by provonar What a mess.Although the pressure was clearly on with the appointment of Harmesh Suniara to the Board (an investment fund doesn't push one of their people on to a Board if everything is going smoothly), I didn't expect Lemos to be forced out so abruptly. (And neither did any of the big shorters, by the look of things.) I would expect the Mark Cubitt / Jutta Meier leadership to make an announcement as soon as possible to steady the ship and make clear how cash flow and client relationships are to be maintained in the short term. Then there will probably be further Board resignations as some of the Lemos appointees are culled (Meier was not from GF, so it's not clear whether she was a Lemos appointee or forced in by one of the funds...). But the much larger issue is what direction can IQE now take? Lemos killed off the technology-focussed approach of Nelson, and now the 'client-need driven' approach of Lemos has been shown to be a turkey. The first approach relies on developing unique IP and then trying to persuade Tier 1/OEMs to include it in their upcoming products; the second approach relies on good OEM relationships where the qualifications lead to mass production orders where IQE implements the IP that the OEM/fabless customer has developed. If both of these approaches cannot be made to work, there's not much left to go for and the whole epitaxy-outsourcing business model is called into question. Lemos wanted to pull in business from the vertically-integrate However, there are other players who do seem to be doing better: VPEC have been eating IQE's lunch in the GaAs space; Landmark have shot up recently with their SoI epitaxy - and IQE previously demonstrated the market's out there, only to be undermined by their own partner (Lumentum) taking the mickey out of making so much money off Apple that Apple sank $100Ms into rival capability in Coherent. So, it's very difficult to see what the best route forward is. Stick with GaAs & GaN epitaxy? Try to push more for co-packaged silicon optics? Head into the SiC space (which is meant to explode in demand over the next ~5 years, but is massively competitive with huge Chinese government subsidies)? Change the business model entirely and try to vertically-integrate I just hope this coup has some slight planning behind it and there are potential new CEOs lined up. However, knowing how the last change in CEO went, I somehow doubt this is the case. This will also negatively affect the Taiwan IPO, as it will reduce investor interest - just what IQE doesn't need and also another reason why the Board now needs to move fast. The next couple of weeks will be telling... |
Posted at 25/10/2024 19:19 by 46maxon IQE is a UK-based semiconductor company that specializes in producing advanced semiconductor materials, primarily for use in technologies like smartphones, telecommunications, and, increasingly, in high-growth areas such as 5G infrastructure and electric vehicles (EVs). Here’s what to consider about IQE as a potential investment:1. Core Business and Market Position • Compound Semiconductors: IQE’s focus on compound semiconductors differentiates it from traditional silicon-based players. Compound semiconductors are vital for high-performance applications, such as photonics (sensors, facial recognition) and power electronics (5G, EVs). As these markets grow, IQE is well-positioned to benefit. • Competitive Position: IQE has strategic partnerships and a strong market position within this niche, though it faces competition from larger semiconductor manufacturers and potential advances in alternative technologies. Evaluating its ability to maintain a technological edge is key. 2. Revenue Volatility and Profitability • Cyclical Revenue: IQE’s revenue can be volatile, partly due to the cyclical nature of the semiconductor industry. Factors such as global semiconductor demand, supply chain constraints, and shifts in smartphone sales influence IQE’s performance significantly. • Profitability: Historically, IQE has faced challenges with consistent profitability, as R&D investments and production costs have impacted margins. If they’re showing signs of improving margins or increased operational efficiency, this would be a positive indicator. 3. Growth Potential in Emerging Technologies • 5G, IoT, and EVs: IQE’s products are aligned with sectors expected to grow rapidly. For example, 5G infrastructure and IoT devices require high-performance semiconductors, where IQE has a role to play. Growth in these areas could directly translate into higher revenues. • Photonic Technologies: IQE also supplies materials for photonic devices, such as lasers and sensors, used in facial recognition, autonomous driving, and other applications. If demand for these technologies grows, IQE may see a positive revenue impact. 4. Financial Health and Valuation • Balance Sheet and Debt: IQE’s debt levels and cash flow are important to examine, particularly given the high costs of R&D and manufacturing in semiconductors. Excessive debt could be a red flag, while a strong balance sheet would provide stability. • Valuation: If IQE is trading at a low valuation relative to its earnings potential and the semiconductor sector, it could be undervalued. Look at metrics like the P/E ratio, price-to-sales ratio, and compare with peers. 5. Risks and Considerations • Reliance on Key Customers: IQE may rely on a small number of large customers, which can add risk if any of these clients reduce their orders. • Technological Risks: Semiconductor technology evolves rapidly. If new materials or methods outperform compound semiconductors, IQE could be at a disadvantage. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
